Navigation Links
Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
Date:6/10/2009

d commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
(Date:11/18/2014)... Brothers Josh and Bryce Benbasat (ages ... PAWSitively Curing Cancer, Inc . in recognition of National ... organization is dedicated to raising funds for pet cancer ... University of Florida College of Veterinary Medicine . ... as the recipient of this vital funding. It will ...
(Date:11/18/2014)... 18, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... with the acquisition of Durata Therapeutics, Inc. by Actavis, ... the termination of PDL,s credit agreement with Durata, which ... $40 million, accrued interest, and prepayment and change of ... structured financing transaction with Durata in which PDL agreed ...
(Date:11/18/2014)... , Nov. 18, 2014  Novira Therapeutics, Inc., a ... treatment of chronic hepatitis B virus (HBV) infection, today ... appointed to its Scientific Advisory Board (SAB).  ... SAB," said Christian S. Schade , Chief Executive ... development experience which will be invaluable to Novira as ...
Breaking Biology Technology:PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3
... AMLN ) will be presenting at the FBR ... 28, 2008 at 9:45 a.m. ET / 6:45,a.m. PT. ... Pharmaceuticals, will be providing a corporate overview., The ... a,recording will be made available following the event. The ...
... AstraZeneca (NYSE:,AZN) announced today that it supports ... the company,s latest step to provide the public,with ... Sponsored by Sens. Charles Grassley of Iowa ... a national registry of payments that,biopharmaceutical companies, device ...
... Biosciences,Corporation (Nasdaq: MATK ) announced that it intends ... 2008 on June 4, 2008, at approximately 4:00,p.m. Eastern ... Martek will,conduct a conference call to discuss the results ... interested parties may listen to the call,live via webcast ...
Cached Biology Technology:AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers 2
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
(Date:11/6/2014)... November 6, 2014 - Insilico Medicine, Inc, a ... and age related diseases announced a research collaboration ... cancer, Champions Oncology, Inc (OTC: CSBR). , "There ... personalized medicine, but Champions Oncology,s TumorGraft technology is ... the chemotherapy regimen experimentally generating vast amounts of ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Scientists from the LSU Museum of Natural Science, or MNS, ... ornithological research programs in the world. This study the ... only shaken up the avian evolutionary tree, but completely redrawn ... heavily upon the LSU MNS, genetic resources collection, will be ...
... DCA groundbreaking new study finds that genes significantly affect ... reasons why people vote and participate in the political ... H. Fowler, Christopher T. Dawes (of UC San Diego) ... California), appears in the May issue of the ...
... together the latest science from research groups around Australia, ... agricultural sectors, with a focus on steps that can ... our climate. , Speaking to the Farm Writers Association ... CSIRO scientist Dr Mark Howden, said it was time ...
Cached Biology News:'Early bird' project really gets the worm 2Why do people vote? Genetic variation in political participation 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Plasmid expressing PLAP reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
Biology Products: